Real Data on Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19 Versus Remdesivir or Favipiravir in Hospitalized COVID Cases

Abstract

Hatem Elalfy*, Tarek Besheer, Ahmed El-Mesery, Abdel-Hady El-Gilany, Mohamed Alegezy, Mahmoud Abdelaziz Soliman, Mohamed Elegezy, Hossam Zaghloul, Mustafa Ahmed Mohamed Neamatallah, Nermin Y Abo El Kheir, Maii Saad, Doaa Khedr, Adel El-Badrawy, Ahmed Ezzat Helal, Mahmoud El-Bendary and Tamer Elhadidy

Background: The pandemic of COVID-19 has forced the health system to incorporate many antiviral drugs into medical field applications. Researchers have started clinical trials to assess the effectiveness of many virus-targeting medications due to the pressing need for a safe and efficient treatment.

Aim: This study examined the the real world data describe effectiveness of nitazoxanide, ribavirin, and ivermectin plus zinc in comparison to those taking remdesivir or favipiravir treatment.

Subject and Methods: Patients inclusion start after approval from Mansoura IRB at April with code number RP.20.05.69. This non-randomized open label-controlled trial included 108 hospitalized patients receiving treatment classified into 3 groups: NRIZ group, favipiravir group, and remdesivir group. They all verified the case with a positive RT-PCR of nasopharyngeal swab.

Results: This trial shows that there are no statistical differences among the 3 groups as regard age, sex, severity, comorbidities, mode of O2 intake, and outcome except for the length of stay at the hospital being lower in the NIRZ group in a Pairwise comparison between the NRIZ group vs. the Remdesivir group (P 0.03).

Conclusion: This trial concluded that NRIZ combination therapy is comparable to either Favipiravir or Remdesivir

HTML PDF